|
1
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE,
Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of
the head and neck. N Engl J Med. 375:1856–1867. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Burtness B, Harrington KJ, Greil R,
Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane
P, Bratland Å, et al: Pembrolizumab alone or with chemotherapy
versus cetuximab with chemotherapy for recurrent or metastatic
squamous cell carcinoma of the head and neck (KENOTE-048): A
randomised, open-label, phase 3 study. Lancet. 394:1915–1928. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Galluzzi L, Senovilla L, Zitvogel L and
Kroemer G: The secret ally: Immunostimulation by anticancer drugs.
Nat Rev Drug Discov. 11:215–233. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Allen CT, Clavijo PE, Van Waes C and Chen
Z: Anti-tumor immunity in head and neck cancer: Understanding the
evidence, how tumors escape and immunotherapeutic approaches.
Cancers (Basel). 7:2397–2414. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Szturz P, Cristina V, Gómez RGH, Bourhis
J, Simon C and Vermorken JB: Cisplatin eligibility issues and
alternative regimens in locoregionally advanced head and neck
cancer: Recommendations for clinical practice. Front Oncol.
9:4642019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ahn MJ, D'Cruz A, Vermorken JB, Chen JP,
Chitapanarux I, Dang HQT, Guminski A, Kannarunimit D, Lin TY, Ng
WT, et al: Clinical recommendations for defining platinum
unsuitable head and neck cancer patient populations on
chemoradiotherapy: A literature review. Oral Oncol. 53:10–16. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rosenberg AJ, Agrawal N, Pearson A, Gooi
Z, Blair E, Cursio J, Juloori A, Ginat D, Howard A, Chin J, et al:
Risk and response adapted de-intensified treatment for
HPV-associated oropharyngeal cancer: Optima paradigm expanded
experience. Oral Oncol. 122:1055662021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hecht M, Gostian AO, Eckstein M, Rutzner
S, Von Der Grün J, Illmer T, Hautmann MG, Klautke G, Laban S,
Brunner T, et al: Safety and efficacy of single cycle induction
treatment with cisplatin/docetaxel/durvalumab/tremelimumab in
locally advanced HNSCC: First results of CheckRad-CD8. J Immunother
Cancer. 8:e0013782020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Semrau S, Gostian AO, Traxdorf M, Eckstein
M, Rutzner S, von der Grün J, Illmer T, Hautmann M, Klautke G,
Laban S, et al: Implementation of double immune checkpoint blockade
increases response rate to induction chemotherapy in head and neck
cancer. Cancers (Basel). 13:19592021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hecht M, Eckstein M, Rutzner S, Von Der
Grün J, Illmer T, Klautke G, Laban S, Hautmann MG, Brunner TB,
Tamaskovics B, et al: Induction chemoimmunotherapy followed by CD8+
immune cell-based patient selection for chemotherapy-free
radioimmunotherapy in locally advanced head and neck cancer. J
Immunother Cancer. 10:e0037472022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dzienis MR, Cundom JE, Fuentes CS, Hansen
AR, Nordlinger MJ, Pastor AV, Oppelt P, Neki A, Gregg RW, Lima PF,
et al: 651O-Pembrolizumab (pembro) + carboplatin (carbo) +
paclitaxel (pacli) as first-line (1L) therapy in
recurrent/metastatic (R/M) head and neck squamous cell carcinoma
(HNSCC): Phase VI KEYNOTE-B10 study. Ann Oncol. 33 (Suppl
7):S295–S322. 2022. View Article : Google Scholar
|
|
12
|
Paz-Ares L, Luft A, Vicente D, Tafreshi A,
Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, et
al: Pembrolizumab plus chemotherapy for squamous non-small-cell
lung cancer. N Engl J Med. 379:2040–2051. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cabezas-Camarero S, Alonso-Ovies A,
Merino-Menéndez S, Cabrera-Martín MN, Plaza-Hernández JC and
Pérez-Segura P: Major pathological response and durable
locoregional control after neoadjuvant
pembrolizumab-carboplatin-paclitaxel in head and neck cancer. Oral
Oncol. 123:1055892021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guigay J, Aupérin A, Fayette J,
Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L,
Capitain O, Cupissol D, et al: Cetuximab, docetaxel, and cisplatin
versus platinum, fluorouracil, and cetuximab as first-line
treatment in patients with recurrent or metastatic head and neck
squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): A multicentre,
open-label, randomised, phase 2 trial. Lancet Oncol. 22:463–475.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vitzthum LK, Feng CH, Noticewala S, Hines
PJ, Nguyen C, Zakeri K, Sojourner EJ, Shen H and Mell LK:
Comparison of comorbidity and frailty indices in patients with head
and neck cancer using an online tool. JCO Clin Cancer Inform.
2:1–9. 2018. View Article : Google Scholar
|
|
16
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tsimberidou AM, Levit LA, Schilsky RL,
Averbuch SD, Chen D, Kirkwood JM, McShane LM, Sharon E, Mileham KF
and Postow MA: Trial reporting in immuno-oncology (TRIO): An
American society of clinical oncology-society for immunotherapy of
cancer statement. J Clin Oncol. 37:72–80. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
de Ruiter EJ, Mulder FJ, Koomen BM, Speel
EJ, van den Hout MFCM, de Roest RH, Bloemena E, Devriese LA and
Willems SM: Comparison of three PD-L1 immunohistochemical assays in
head and neck squamous cell carcinoma (HNSCC). Mod Pathol.
34:1125–1132. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cabezas-Camarero S, Cabrera-Martin MN,
Saiz-Pardo Sanz M and Perez-Segura P: Major and durable response to
second-line pembrolizumab-carboplatin-paclitaxel in an oral cavity
cancer patient. Anticancer Drugs. 32:580–584. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE,
Even C, et al: Nivolumab vs investigator's choice in recurrent or
metastatic squamous cell carcinoma of the head and neck: 2-Year
long-term survival update of CheckMate 141 with analyses by tumor
PD-L1 expression. Oral Oncol. 81:45–51. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cohen EEW, Soulières D, Le Tourneau C,
Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R,
et al: Pembrolizumab versus methotrexate, docetaxel, or cetuximab
for recurrent or metastatic head-and-neck squamous cell carcinoma
(KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet.
393:156–167. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Harrington KJ, Burtness B, Greil R,
Soulières D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Basté N,
Neupane P, et al: Pembrolizumab with or without chemotherapy in
recurrent or metastatic head and neck squamous cell carcinoma:
Updated results of the phase III KEYNOTE-048 study. J Clin Oncol.
Oct 11–2022.(Epub ahead of print). View Article : Google Scholar
|
|
23
|
Saleh K, Daste A, Martin N, Pons-Tostivint
E, Auperin A, Herrera-Gomez RG, Baste-Rotllan N, Bidault F, Guigay
J, Le Tourneau C, et al: Response to salvage chemotherapy after
progression on immune checkpoint inhibitors in patients with
recurrent and/or metastatic squamous cell carcinoma of the head and
neck. Eur J Cancer. 121:123–129. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pestana RC, Becnel M, Rubin ML, Torman DK,
Crespo J, Phan J, Hanna E, Bell D, Glisson BS, Johnson JM, et al:
Response rates and survival to systemic therapy after immune
checkpoint inhibitor failure in recurrent/metastatic head and neck
squamous cell carcinoma. Oral Oncol. 101:1045232020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cabezas-Camarero S, Cabrera-Martín MN,
Merino-Menéndez S, Paz-Cabezas M, García-Barberán V, Sáiz-Pardo
Sanz M, Iglesias-Moreno M, Alonso-Ovies A and Pérez-Segura P:
Safety and efficacy of cetuximab-based salvage chemotherapy after
checkpoint inhibitors in head and neck cancer. Oncologist.
26:e1018–e1035. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Suzuki S, Toyoma S, Kawasaki Y, Koizumi K,
Iikawa N, Shiina K, Endo T, Abe T, Kouga T and Yamada T: Clinical
outcomes of cetuximab and paclitaxel after progression on immune
checkpoint inhibitors in recurrent or metastatic head and neck
squamous cell carcinoma. Medicina (Kaunas). 57:11512021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fushimi C, Okamoto I, Matsuki T, Masubuchi
T, Okada T, Sato H, Tsukahara K, Kondo T, Yamashita T, Hanyu K, et
al: Salvage chemotherapy after nivolumab for recurrent or
metastatic head and neck carcinoma. Anticancer Res. 40:5277–5283.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Katayama Y, Shimamoto T, Yamada T, Takeda
T, Yamada T, Shiotsu S, Chihara Y, Hiranuma O, Iwasaku M, Kaneko Y,
et al: Retrospective efficacy analysis of immune checkpoint
inhibitor rechallenge in patients with non-small cell lung cancer.
J Clin Med. 9:1022019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gobbini E, Toffart AC, Pérol M, Assié JB,
Duruisseaux M, Coupez D, Dubos C, Westeel V, Delaunay M, Guisier F,
et al: Immune checkpoint inhibitors rechallenge efficacy in
non-small-cell lung cancer patients. Clin Lung Cancer.
21:e3497–e510. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wakasugi T, Takeuchi S, Ohkubo JI and
Suzuki H: Retreatment with nivolumab for patients with recurrent
and/or metastatic head and neck cancer. Acta Otolaryngol.
142:206–212. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Katsumata N, Yasuda M, Isonishi S,
Takahashi F, Michimae H, Kimura E, Aoki D, Jobo T, Kodama S,
Terauchi F, et al: Long-term results of dose-dense paclitaxel and
carboplatin versus conventional paclitaxel and carboplatin for
treatment of advanced epithelial ovarian, fallopian tube, or
primary peritoneal cancer (JCOG 3016): A randomised, controlled,
open-label trial. Lancet Oncol. 14:1020–1026. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hitt R, Irigoyen A, Cortes-Funes H, Grau
JJ, García-Sáenz JA and Cruz-Hernández JJ; Spanish Head and Neck
Cancer Cooperative Group (TTCC), : Phase II study of the
combination of cetuximab and weekly paclitaxel in the first-line
treatment of patients with recurrent and/or metastatic squamous
cell carcinoma of the head and neck. Ann Oncol. 23:1016–1022. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chevalier T, Daste A, Saada-Bouzid E,
Loundou A, Peyraud F, Lambert T, Le Tourneau C, Peyrade F, Dupuis
C, Alfonsi M, et al: Cetuximab combined with paclitaxel or
paclitaxel alone for patients with recurrent or metastatic head and
neck squamous cell carcinoma progressing after EXTREME. Cancer Med.
10:3952–3963. 2021. View Article : Google Scholar : PubMed/NCBI
|
